Denali Therapeutics' GAAP loss for 3 months of 2022 was $65.22 million, down 6.9% from $70.041 million in the prior year. Revenue increased 5.32 times to $42.141 million from $7.923 million a year earlier.

Denali Therapeutics' GAAP loss for 2021 was $290.581 million, compared to a profit of $71.136 million in the previous year. Revenue decreased sevenfold to $48.661 million from $335.659 million a year earlier.

Denali Therapeutics' GAAP loss for 9M 2021 was $215.32 million, up 23.9% from $173.749 million in the prior year. Revenue increased 91.8% to $36.147 million from $18.844 million a year earlier.

Denali Therapeutics reported a GAAP loss of $130.732 million for 6 months of 2021, up 13.2% from $115.521 million in the prior year. Revenue increased 3.26 times to $30.862 million from $9.451 million a year earlier.